IL97100A - History of 3- Piperidino-4- Hydroxychroman Intermediates for their preparation and neuroprotective preparations - Google Patents

History of 3- Piperidino-4- Hydroxychroman Intermediates for their preparation and neuroprotective preparations

Info

Publication number
IL97100A
IL97100A IL9710091A IL9710091A IL97100A IL 97100 A IL97100 A IL 97100A IL 9710091 A IL9710091 A IL 9710091A IL 9710091 A IL9710091 A IL 9710091A IL 97100 A IL97100 A IL 97100A
Authority
IL
Israel
Prior art keywords
compound
hydroxy
mmol
cis
ether
Prior art date
Application number
IL9710091A
Other languages
English (en)
Hebrew (he)
Other versions
IL97100A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL97100A0 publication Critical patent/IL97100A0/xx
Publication of IL97100A publication Critical patent/IL97100A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/48Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/52Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL9710091A 1990-02-06 1991-01-30 History of 3- Piperidino-4- Hydroxychroman Intermediates for their preparation and neuroprotective preparations IL97100A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1990/000674 WO1991012005A1 (en) 1990-02-06 1990-02-06 Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs

Publications (2)

Publication Number Publication Date
IL97100A0 IL97100A0 (en) 1992-03-29
IL97100A true IL97100A (en) 1996-06-18

Family

ID=22220666

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9710091A IL97100A (en) 1990-02-06 1991-01-30 History of 3- Piperidino-4- Hydroxychroman Intermediates for their preparation and neuroprotective preparations

Country Status (29)

Country Link
US (1) US5356905A (ru)
EP (1) EP0441506B1 (ru)
JP (1) JPH0768214B2 (ru)
KR (1) KR930011041B1 (ru)
CN (1) CN1029960C (ru)
AT (1) ATE108787T1 (ru)
AU (1) AU626490B2 (ru)
BR (1) BR9100490A (ru)
CA (1) CA2035653C (ru)
CZ (1) CZ286218B6 (ru)
DE (2) DE69102893T4 (ru)
DK (1) DK0441506T3 (ru)
EG (1) EG19643A (ru)
ES (1) ES2056571T3 (ru)
FI (1) FI94957C (ru)
HU (1) HU222726B1 (ru)
IE (1) IE63836B1 (ru)
IL (1) IL97100A (ru)
MX (1) MX24433A (ru)
MY (1) MY105293A (ru)
NO (1) NO178399C (ru)
NZ (1) NZ237025A (ru)
PH (1) PH31061A (ru)
PL (1) PL164866B1 (ru)
PT (1) PT96664B (ru)
RU (1) RU2099339C1 (ru)
SK (1) SK281729B6 (ru)
WO (1) WO1991012005A1 (ru)
ZA (1) ZA91830B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018502A1 (en) * 1991-04-18 1992-10-29 Pfizer Inc. Prodrug esters of phenolic 2-piperidino-1-alkanols
US5594007A (en) * 1991-04-18 1997-01-14 Pfizer Inc. Method for treating spinal cord trauma with phenolic 2-piperidino-1-alkanols
US5436255A (en) * 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
EP0741724B1 (en) * 1994-01-31 1999-08-11 Pfizer Inc. Neuroprotective chroman compounds
NZ284852A (en) * 1994-08-18 1998-06-26 Pfizer 3-(piperidin-1-yl)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidin-1-yl) alkanol derivatives; medicaments; used as a neuroprotective agent
EP0828513B1 (en) 1995-05-26 2004-01-21 Pfizer Inc. Combinations for the treatment of parkinsonism containing selective nmda antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
AU1153601A (en) 1999-10-29 2001-05-08 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole NMDA NR2B antagonists
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
EA005974B1 (ru) 2001-02-23 2005-08-25 Мерк Энд Ко., Инк. N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
JP2005511478A (ja) 2001-04-03 2005-04-28 メルク エンド カムパニー インコーポレーテッド N−置換非アリール複素環アミジル系nmda/nr2b拮抗薬
WO2005034878A2 (en) * 2003-10-08 2005-04-21 President And Fellows Of Harvard College Pyrovalerone analogs and therapeutic uses thereof
DK1689721T3 (da) * 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazolderivater som GSK-3-ihibitorer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3294804A (en) * 1961-01-27 1966-12-27 Sterling Drug Inc 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
FR5733M (ru) * 1966-09-27 1968-01-22
GB1495526A (en) * 1974-05-31 1977-12-21 Beecham Group Ltd Chroman derivatives
US4016281A (en) * 1975-02-22 1977-04-05 Merck Patent Gesellschaft Mit Beschrankter Haftung Tetralone and indanone compounds
DE2507782A1 (de) * 1975-02-22 1976-09-02 Merck Patent Gmbh Tetralon- und indanon-derivate sowie verfahren zu ihrer herstellung
GB2107706A (en) * 1981-09-25 1983-05-05 Beecham Group Plc Benzopyrans
EP0093534A1 (en) * 1982-04-28 1983-11-09 Beecham Group Plc Novel chromanols
GB8308064D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds

Also Published As

Publication number Publication date
NZ237025A (en) 1992-11-25
JPH04211058A (ja) 1992-08-03
DE69102893D1 (de) 1994-08-25
CZ286218B6 (cs) 2000-02-16
CA2035653A1 (en) 1991-08-07
IE63836B1 (en) 1995-06-14
ZA91830B (en) 1992-09-30
MY105293A (en) 1994-09-30
RU2099339C1 (ru) 1997-12-20
FI923527A (fi) 1992-08-05
IE910372A1 (en) 1991-08-14
DE69102893T2 (de) 1994-11-03
NO178399B (no) 1995-12-11
EP0441506B1 (en) 1994-07-20
MX24433A (es) 1993-05-01
SK281729B6 (sk) 2001-07-10
NO923081L (no) 1992-08-05
EP0441506A3 (en) 1991-11-21
ES2056571T3 (es) 1994-10-01
KR930011041B1 (ko) 1993-11-20
WO1991012005A1 (en) 1991-08-22
FI94957B (fi) 1995-08-15
JPH0768214B2 (ja) 1995-07-26
PL288949A1 (en) 1991-07-29
BR9100490A (pt) 1991-10-29
AU7029391A (en) 1991-09-05
CS25091A3 (en) 1991-09-15
CA2035653C (en) 1999-12-21
IL97100A0 (en) 1992-03-29
NO178399C (no) 1996-03-20
DK0441506T3 (da) 1994-09-05
FI94957C (fi) 1995-11-27
CN1053923A (zh) 1991-08-21
EP0441506A2 (en) 1991-08-14
ATE108787T1 (de) 1994-08-15
PT96664B (pt) 1998-07-31
HU222726B1 (hu) 2003-09-29
EG19643A (en) 1995-09-30
KR910015568A (ko) 1991-09-30
PH31061A (en) 1998-02-05
US5356905A (en) 1994-10-18
DE9101346U1 (ru) 1991-06-06
PT96664A (pt) 1991-10-31
PL164866B1 (pl) 1994-10-31
NO923081D0 (no) 1992-08-05
CN1029960C (zh) 1995-10-11
AU626490B2 (en) 1992-07-30
DE69102893T4 (de) 1995-08-10
FI923527A0 (fi) 1992-08-05

Similar Documents

Publication Publication Date Title
EP0441506B1 (en) Neuroprotective 3-piperidino-4-hydrosychroman derivatives
EP0554247B1 (en) Neuroprotective indolone and related derivatives
JPH0680634A (ja) ピペラジニル−およびピペリジニル−シクロヘキサノール化合物
US5436255A (en) Method of treating diseases susceptable to treatment by blocking NMDA-receptors
AU684874B2 (en) Heterocyclic compounds for the treatment of cns and cardiovascular disorders
US5498610A (en) Neuroprotective indolone and related derivatives
JPH11315063A (ja) 光学活性な2―アミノ―1,2,3,4―テトラヒドロナフタレンおよび3―アミノクロマンの製法
KR940003491B1 (ko) 4,4-이중 치환된 피페리딘 유도체와 그 제조방법 및 상기 화합물을 함유하는 약제학적 조성물
JPH06287190A (ja) 新規な3−アミノクロマンスピロ化合物、それらの製造法およびそれらを含む薬学組成物
US4593037A (en) 1,3-disubstituted piperidine compounds as neuroleptic agents
AU705431B2 (en) Indanylpiperidines as melatonergic agents
MXPA97008612A (en) Derivatives of alpha- (alkylphenyl replaced) -4- (hydroxydyphenyl methyl) -1-piperidinbutanol, its preparation and its use as antihistamines, antialergic agents, and broncodilated
EP0502031B1 (en) N-substituted azaheterocyclic carboxylic acids and a pharmaceutical composition
US4788201A (en) 3-methylenespiro (benzofuranpiperidines)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees